Advaxis, City of Hope to Develop Listeria-Based Cancer Vaccine | GenomeWeb
Advaxis, a biotech firm developing cancer vaccines based on the Listeria monocytogenes bacterium, has inked a research collaboration with City of Hope to develop a new cancer vaccine targeting the p53 protein.
 
Although the collaboration at this point is “purely academic” as opposed to sponsored research, it could lead to the development of additional intellectual property in which both Advaxis and City of Hope would have a stake, according to an Advaxis official.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.